Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
Guidance supports use when standard therapies fail
Original title: “NICE backs Tryngolza for FCS treatment”
case report of familial chylomicronemia syndrome with infantile onset one year follow up on lipid profile and growth development
Original title: “A Case Report of Familial Chylomicronemia Syndrome With Infantile Onset: One-Year Follow-Up on Lipid Profile and Growth Development.”
EMA has recommended granting a marketing authorisation in the European Union (EU) for Redemplo (plozasiran) to treat adults with familial chylomicronaemia syndrome (FCS).FCS is…
Original title: “New medicine to reduce triglycerides in adults with familial chylomicronaemia syndrome”
Through Rare Disease Day activities ... patient voices and works to ensure that the unique needs of this ultra-rare community are recognized by healthcare systems, researchers, and policymakers. For more information about Familial Chylomicronemia Syndrome or how to support Rare Disease Day efforts, visit www.livingwithfcs.org. About the FCS Foundation The FCS Foundation was established to connect individuals affected by Familial Chylomicronemia Syndrome and to promote advocacy, education, ... Through Rare Disease Day activities and year-round efforts, the Foundation amplifies patient voices and works to ensure that the unique needs of this ultra-rare community are recognized by healthcare systems, researchers, and policymakers. For more information about Familial Chylomicronemia Syndrome or how to support Rare Disease Day efforts, visit www.livingwithfcs.org. About the FCS Foundation The FCS Foundation was established to connect individuals affected by Familial Chylomicronemia Syndrome and to promote advocacy, education, and support. 27, 2026 /PRNewswire/ -- Rare Disease Day, observed each year globally on the last day of February to shine a spotlight on the millions of individuals affected by rare conditions, gives the FCS Foundation an important platform to raise awareness about Familial Chylomicronemia Syndrome (FCS) — a rare genetic metabolic disorder that profoundly impacts daily life for patients and families. "Rare Disease Day reminds us that visibility matters," said Melissa Goetz, Co-President of FCS Foundation. "While FCS affects a small number of individuals, the challenges faced by our community are shared by millions living with rare diseases worldwide. Today, and every day, we honor the strength of patients and caregivers, and advocate for greater awareness, support, and progress in research that can improve lives."
Original title: “FCS Foundation Marks Rare Disease Day to Elevate Awareness and Support for Families Living with Familial Chylomicronemia Syndrome”
Through Rare Disease Day activities ... patient voices and works to ensure that the unique needs of this ultra-rare community are recognized by healthcare systems, researchers, and policymakers. For more information about Familial Chylomicronemia Syndrome or how to support Rare Disease Day efforts, visit www.livingwithfcs.org. About the FCS Foundation The FCS Foundation was established to connect individuals affected by Familial Chylomicronemia Syndrome and to promote advocacy, education, ... Through Rare Disease Day activities and year-round efforts, the Foundation amplifies patient voices and works to ensure that the unique needs of this ultra-rare community are recognized by healthcare systems, researchers, and policymakers. For more information about Familial Chylomicronemia Syndrome or how to support Rare Disease Day efforts, visit www.livingwithfcs.org. About the FCS Foundation The FCS Foundation was established to connect individuals affected by Familial Chylomicronemia Syndrome and to promote advocacy, education, and support. 27, 2026 /PRNewswire/ -- Rare Disease Day, observed each year globally on the last day of February to shine a spotlight on the millions of individuals affected by rare conditions, gives the FCS Foundation an important platform to raise awareness about Familial Chylomicronemia Syndrome (FCS) — a rare genetic metabolic disorder that profoundly impacts daily life for patients and families. "Rare Disease Day reminds us that visibility matters," said Melissa Goetz, Co-President of FCS Foundation. "While FCS affects a small number of individuals, the challenges faced by our community are shared by millions living with rare diseases worldwide. Today, and every day, we honor the strength of patients and caregivers, and advocate for greater awareness, support, and progress in research that can improve lives."
Original title: “FCS Foundation Marks Rare Disease Day to Elevate Awareness and Support for Families Living with Familial Chylomicronemia Syndrome”